Director David R. Epstein filed a Form 4 with the SEC on November 19, 2026, disclosing a purchase of 5,000 common shares of AgomAb Therapeutics NV on November 17, 2026.
Key Highlights
- Reporting person: David R. Epstein, identified as a Director of AgomAb Therapeutics NV (NASDAQ:AGMB).
- Transaction: Purchase (transaction code P) of 5,000 common shares on November 17, 2026.
- Price paid: $5.57 per share, according to the filing.
- Post-transaction ownership: Epstein directly holds 59,980 common shares following the reported transaction.
- ADS note: The filing states the common shares may be represented by American Depositary Shares, each of which currently represents one common share.
Epstein's November 2026 Open-Market Purchase of AgomAb Common Shares
According to the Form 4 filed on November 19, 2026, David R. Epstein, a director of AgomAb Therapeutics NV, acquired 5,000 common shares of the company on November 17, 2026, at a price of $5.57 per share. The transaction is coded "P," indicating an open-market purchase. The filing reports no derivative securities activity.
Following the reported transaction, Epstein's direct beneficial ownership stands at 59,980 common shares, as stated in the filing. The shares are held directly. The filing was signed by Ellen Lefever as attorney-in-fact on behalf of the reporting person and was submitted to the SEC on November 19, 2026.
The filing includes a note that the common shares may be represented by American Depositary Shares, with each ADS currently representing one common share. No amendment date is listed, indicating this is an original filing. Table II, covering derivative securities, contains no reported transactions.
What Was Disclosed
A Form 4 filed by Director David R. Epstein reported the purchase of 5,000 AgomAb Therapeutics NV common shares at $5.57 each on November 17, 2026, bringing his direct beneficial ownership to 59,980 shares.




Please wait processing your request...